UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
WASHINGTON — Joe Biden recently underwent skin cancer surgery, a spokesperson confirmed to USA TODAY, just months after the former president was diagnosed with prostate cancer. According to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback